Dutch Oncology COVID-19 consortium : Outcome of COVID-19 in patients with cancer in a nationwide cohort study
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved..
AIM OF THE STUDY: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19.
METHODS: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients' characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible.
RESULTS: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age ≥65 years (p < 0.001), male gender (p = 0.035), prior or other malignancy (p = 0.045) and active diagnosis of haematological malignancy (p = 0.046) or lung cancer (p = 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (≥65 years).
CONCLUSION: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 141(2020) vom: 30. Dez., Seite 171-184 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Joode, Karlijn [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 04.01.2021 Date Revised 18.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2020.09.027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317290231 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317290231 | ||
| 003 | DE-627 | ||
| 005 | 20231225162941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2020.09.027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1057.xml |
| 035 | |a (DE-627)NLM317290231 | ||
| 035 | |a (NLM)33161241 | ||
| 035 | |a (PII)S0959-8049(20)31035-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Joode, Karlijn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dutch Oncology COVID-19 consortium |b Outcome of COVID-19 in patients with cancer in a nationwide cohort study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2021 | ||
| 500 | |a Date Revised 18.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a AIM OF THE STUDY: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19 | ||
| 520 | |a METHODS: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients' characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible | ||
| 520 | |a RESULTS: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age ≥65 years (p < 0.001), male gender (p = 0.035), prior or other malignancy (p = 0.045) and active diagnosis of haematological malignancy (p = 0.046) or lung cancer (p = 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (≥65 years) | ||
| 520 | |a CONCLUSION: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cancer treatment | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Pandemic | |
| 700 | 1 | |a Dumoulin, Daphne W |e verfasserin |4 aut | |
| 700 | 1 | |a Tol, Jolien |e verfasserin |4 aut | |
| 700 | 1 | |a Westgeest, Hans M |e verfasserin |4 aut | |
| 700 | 1 | |a Beerepoot, Laurens V |e verfasserin |4 aut | |
| 700 | 1 | |a van den Berkmortel, Franchette W P J |e verfasserin |4 aut | |
| 700 | 1 | |a Mutsaers, Pim G N J |e verfasserin |4 aut | |
| 700 | 1 | |a van Diemen, Nico G J |e verfasserin |4 aut | |
| 700 | 1 | |a Visser, Otto J |e verfasserin |4 aut | |
| 700 | 1 | |a Oomen-de Hoop, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Bloemendal, Haiko J |e verfasserin |4 aut | |
| 700 | 1 | |a van Laarhoven, Hanneke W M |e verfasserin |4 aut | |
| 700 | 1 | |a Hendriks, Lizza E L |e verfasserin |4 aut | |
| 700 | 1 | |a Haanen, John B A G |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Elisabeth G E |e verfasserin |4 aut | |
| 700 | 1 | |a Dingemans, Anne-Marie C |e verfasserin |4 aut | |
| 700 | 1 | |a van der Veldt, Astrid A M |e verfasserin |4 aut | |
| 700 | 0 | |a DOCC Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a van Loenhout, C J |e investigator |4 oth | |
| 700 | 1 | |a van der Leest, C H |e investigator |4 oth | |
| 700 | 1 | |a Becker-Commissaris, A |e investigator |4 oth | |
| 700 | 1 | |a Borgers, J S W |e investigator |4 oth | |
| 700 | 1 | |a Terhegggen, F |e investigator |4 oth | |
| 700 | 1 | |a van den Borne, B E E M |e investigator |4 oth | |
| 700 | 1 | |a van Warmerdam, L J C |e investigator |4 oth | |
| 700 | 1 | |a van Leeuwen, L |e investigator |4 oth | |
| 700 | 1 | |a van der Meer, F S |e investigator |4 oth | |
| 700 | 1 | |a Tiemessen, M A |e investigator |4 oth | |
| 700 | 1 | |a van Diepen, D M |e investigator |4 oth | |
| 700 | 1 | |a Klaver, Y |e investigator |4 oth | |
| 700 | 1 | |a Hamberg, A P |e investigator |4 oth | |
| 700 | 1 | |a Libourel, E J |e investigator |4 oth | |
| 700 | 1 | |a Strobbe, L |e investigator |4 oth | |
| 700 | 1 | |a Cloos, M |e investigator |4 oth | |
| 700 | 1 | |a Geraedts, E J |e investigator |4 oth | |
| 700 | 1 | |a Drooger, J C |e investigator |4 oth | |
| 700 | 1 | |a Heller, R |e investigator |4 oth | |
| 700 | 1 | |a de Groot, J W B |e investigator |4 oth | |
| 700 | 1 | |a Stigt, J A |e investigator |4 oth | |
| 700 | 1 | |a Nuij, V J A A |e investigator |4 oth | |
| 700 | 1 | |a Pitz, C C M |e investigator |4 oth | |
| 700 | 1 | |a Slingerland, M |e investigator |4 oth | |
| 700 | 1 | |a Borm, F J |e investigator |4 oth | |
| 700 | 1 | |a Haberkorn, B C M |e investigator |4 oth | |
| 700 | 1 | |a Westeinde, S C van 't |e investigator |4 oth | |
| 700 | 1 | |a Aarts, M J B |e investigator |4 oth | |
| 700 | 1 | |a van Putten, J W G |e investigator |4 oth | |
| 700 | 1 | |a Youssef, M |e investigator |4 oth | |
| 700 | 1 | |a Cirkel, G A |e investigator |4 oth | |
| 700 | 1 | |a Herder, G J M |e investigator |4 oth | |
| 700 | 1 | |a van Rooijen, C R |e investigator |4 oth | |
| 700 | 1 | |a Citgez, E |e investigator |4 oth | |
| 700 | 1 | |a Barlo, N P |e investigator |4 oth | |
| 700 | 1 | |a Scholtes, B M J |e investigator |4 oth | |
| 700 | 1 | |a Koornstra, R H T |e investigator |4 oth | |
| 700 | 1 | |a Claessens, N J M |e investigator |4 oth | |
| 700 | 1 | |a Faber, L M |e investigator |4 oth | |
| 700 | 1 | |a Rikers, C H |e investigator |4 oth | |
| 700 | 1 | |a van de Wetering, R A W |e investigator |4 oth | |
| 700 | 1 | |a Veurink, G L |e investigator |4 oth | |
| 700 | 1 | |a Bouter, B W |e investigator |4 oth | |
| 700 | 1 | |a Houtenbos, I |e investigator |4 oth | |
| 700 | 1 | |a Bard, M P L |e investigator |4 oth | |
| 700 | 1 | |a Herbschleb, K H |e investigator |4 oth | |
| 700 | 1 | |a Kastelijn, E A |e investigator |4 oth | |
| 700 | 1 | |a Brocken, P |e investigator |4 oth | |
| 700 | 1 | |a Douma, G |e investigator |4 oth | |
| 700 | 1 | |a Jalving, M |e investigator |4 oth | |
| 700 | 1 | |a Hiltermann, T J N |e investigator |4 oth | |
| 700 | 1 | |a Schuurbiers-Siebers, O C J |e investigator |4 oth | |
| 700 | 1 | |a Suijkerbuijk, K P M |e investigator |4 oth | |
| 700 | 1 | |a van Lindert, A S R |e investigator |4 oth | |
| 700 | 1 | |a van de Wouw, A J |e investigator |4 oth | |
| 700 | 1 | |a van den Boogaart, V E M |e investigator |4 oth | |
| 700 | 1 | |a Bakker, S D |e investigator |4 oth | |
| 700 | 1 | |a Looysen, E |e investigator |4 oth | |
| 700 | 1 | |a Peerdeman, A L |e investigator |4 oth | |
| 700 | 1 | |a de Jong, W K |e investigator |4 oth | |
| 700 | 1 | |a Siemerink, E J M |e investigator |4 oth | |
| 700 | 1 | |a Staal, A J |e investigator |4 oth | |
| 700 | 1 | |a Franken, B |e investigator |4 oth | |
| 700 | 1 | |a van Geffen, W H |e investigator |4 oth | |
| 700 | 1 | |a Bootsma, G P |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 141(2020) vom: 30. Dez., Seite 171-184 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2020 |g day:30 |g month:12 |g pages:171-184 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2020.09.027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2020 |b 30 |c 12 |h 171-184 | ||